LipoGalen™ – innovative polyglycerol esters

IOI Oleo launched a new family of functional, lipid-based excipients, the polyglycerol esters at CPhI 2025.

As the CPhI 2026 is coming closer we use the time for a small review.

After intensive and dedicated research and development plus countless hours of brainstorming sessions, IOI Oleo GmbH unveiled last year :

LipoGalen® was their newly introduced brand.

This launch marked a major milestone for them. LipoGalen® was born, as they put it,  “out of a deep understanding of the evolving challenges in pharmaceutical formulation. In contrast to common triglycerides, it crystallizes in one stable modification and does not show any polymorphism”.

LipoGalen™ offers a versatile, forward-thinking platform designed to empower innovation across a wide range of applications:

• Rectal and vaginal dosage forms: A novel lipid base that offers new possibilities in the formulation development of such products, with advantages for patients.
• Controlled-release tablets: Matrix systems that allow precise control over drug-release profiles throughout the shelf-life, because of the superior properties of LipoGalen® over traditional triglycerides.
• Solubilization and bioavailability enhancement: Perfect for hot melt extrusion, improving the performance of poorly soluble APIs, while offering the chance of working at reduced processing temperatures compared to the established polymers in this field of application.
• Taste masking: Effective via hot melt coating, helping improve patient compliance.
• Lubrication for tableting: Optimized for continuous manufacturing processes.
• Dermal formulations: Free from paraffins, supporting clean-label, skin-friendly solutions.
• Advanced delivery systems: Suitable for lipid nanoparticles and nano-emulsions, including inhalation therapies.
• 3D-printing: Compatible with melt extrusion techniques for personalized medicine and cutting-edge dosage forms.

LipoGalen® can elevate your formulation strategies and open up exciting new possibilities in drug delivery.

A new generation of lipid based excipients

More than 75% of new chemical entities are poorly soluble and require bioavailability-enhancing excipients. The application of excipients in advanced pharmaceutical processes, aligned with advanced approaches towards personalized medicine, requires special features. Lipid-based excipients (LBEs) are „natural contenders“ for the tasks. However, until now, it has not been possible to fully exploit the potential of LBEs. The main challenge is the unstable solid state of current LBEs, e.g. polymorphism, leading to instability of the final dosage form. Compared to polymers, the low melting temperature of liquids, combined with highly crystalline arrangement, limits their application in advanced pharmaceutical processes.

Reason why

Read the original article here

Source: IOI Oleo, website LipoGalen™

Interested in more information about IOI Oleo excipients here?